



## Xenon Pharmaceuticals to Present at the Jefferies 2016 Healthcare Conference

June 2, 2016

BURNABY, British Columbia, June 02, 2016 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's President and Chief Executive Officer, will present a corporate update at the Jefferies 2016 Healthcare Conference in New York City on Wednesday, June 8, 2016 at 11:30 am ET.

A live audio webcast of the presentation will be available on the investors section of Xenon's website at [www.xenon-pharma.com](http://www.xenon-pharma.com) and will be available for replay for 90 days following the event.

### **About Xenon Pharmaceuticals Inc.**

Xenon is a clinical-stage biopharmaceutical company discovering and developing a pipeline of differentiated therapeutics for orphan indications that it intends to commercialize on its own and for larger market indications that the company intends to partner with global pharmaceutical companies. Xenon has built a core enabling discovery platform, referred to as Extreme Genetics, for the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies. Xenon's Extreme Genetics platform has yielded the first approved gene therapy product in the European Union and a broad development pipeline and multiple pharmaceutical partnerships, including with Teva and Genentech. For more information, please visit [www.xenon-pharma.com](http://www.xenon-pharma.com).

Investor/Media Contact:

Jodi Regts

Senior Director, Corporate Affairs

Xenon Pharmaceuticals Inc.

Phone: 604.484.3353

Email: [investors@xenon-pharma.com](mailto:investors@xenon-pharma.com)



Xenon Pharmaceuticals Inc.